10-Q: Tempest Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics reports a net loss of $7.9 million for the first quarter of 2024, while advancing its clinical programs and preparing for a pivotal study.

Summary

• Tempest Therapeutics, a clinical-stage oncology company, announced its financial results for the first quarter of 2024, reporting a net loss of $7.9 million.
• The company's cash and cash equivalents totaled $32.3 million as of March 31, 2024.
• Research and development expenses were $4.34 million for the quarter, while general and administrative expenses were $3.63 million.
• Tempest is advancing its two clinical programs, TPST-1120 and TPST-1495, and plans to meet with the FDA in 2024 to discuss a pivotal Phase 3 trial for TPST-1120 in first-line liver cancer.
• The company sold 56,288 shares of common stock through its at-the-market offering program, generating net proceeds of approximately $0.3 million.
• As of March 31, 2024, approximately $57.3 million remained available for sale under the ATM Program.
• The company believes its existing cash will be sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is making progress in its clinical programs and has sufficient cash for the next 12 months, it is also experiencing significant losses and will need to raise additional capital. The company is also facing significant risks and uncertainties, which tempers the overall sentiment.

Positives

• The company is actively advancing its clinical programs, TPST-1120 and TPST-1495.
• Tempest is planning to meet with the FDA to discuss a pivotal Phase 3 trial for TPST-1120, indicating progress in its lead program.
• The company has sufficient cash to fund operations for at least the next 12 months.
• The company has $57.3 million remaining available under its ATM program for future capital raising.

Negatives

• The company reported a net loss of $7.9 million for the first quarter of 2024.
• The company has an accumulated deficit of $173.2 million.
• The company has not generated any revenue from product sales.
• The company is dependent on raising additional capital to continue operations.

Risks

• The company has a history of operating losses and may not achieve or sustain profitability.
• The company will need to raise additional funding to finance its operations, which may not be available on acceptable terms or at all.
• The terms of the loan agreement with Oxford Finance provide Oxford with a lien against all of the company's assets, including intellectual property.
• The company faces significant competition in an environment of rapid technological change.
• The FDA regulatory approval process is lengthy and time-consuming, and the company may experience significant delays in the clinical development and regulatory approval of its product candidates.
• The company's success depends in part on its ability to obtain, maintain and protect its intellectual property.
• The trading price of the shares of the company's common stock has been and is likely to continue to be volatile.

Future Outlook

The company expects to incur significant expenses and increasing operating losses for at least the next several years as it continues the clinical development of its product candidates. Management believes that its existing cash and cash equivalents will be sufficient to fund the company's cash requirements for at least 12 months following the issuance of these financial statements. The company intends to raise additional capital through the issuance of additional debt or equity, including in connection with potential merger opportunities, or through business development activities.

Management Comments

• Management believes that its existing cash and cash equivalents will be sufficient to fund the Company's cash requirements for at least 12 months following the issuance of these financial statements.
• The company intends to raise additional capital through the issuance of additional debt or equity including in connection with potential merger opportunities, or through business development activities.

Industry Context

Tempest Therapeutics is operating in the competitive oncology space, where many companies are developing novel cancer therapies. The company's focus on dual-mechanism small molecules and its progress in clinical trials position it as a potential player in the market. The company's lead program, TPST-1120, is poised to begin a pivotal study in first-line liver cancer, which is a significant milestone in the company's development.

Comparison to Industry Standards

• The company's cash burn rate of approximately $7.9 million per quarter is typical for a clinical-stage biotech company, but it will need to secure additional funding to continue operations.
• The company's focus on novel targets like PPAR and EP2/EP4 receptors is consistent with the industry trend of exploring new mechanisms of action for cancer treatment.
• The company's clinical trial results for TPST-1120, showing a 30% confirmed objective response rate, are competitive with other therapies in the first-line liver cancer setting.
• The company's at-the-market offering program is a common method for raising capital in the biotech industry, but it can be dilutive to existing shareholders.
• The company's reliance on third-party manufacturers is also typical for a company of its size, but it introduces risks related to supply chain and quality control.

Stakeholder Impact

• Shareholders may experience dilution due to potential future equity offerings.
• Employees may be impacted by the company's financial performance and future capital raising efforts.
• Patients may benefit from the development of new cancer therapies.
• Creditors may be impacted by the company's debt obligations and ability to repay loans.

Next Steps

• Advance TPST-1120 into a pivotal study in first-line HCC patients.
• Explore TPST-1495 beyond original tumor types of interest.
• Complete the ongoing combination arm in patients with advanced endometrial cancer and report the data in 2024.
• Advance TPST-1495 into a Phase 2 study in patients with the Cancer Prevention Clinical Trials Network in 2024, subject to final approval.

Key Dates

Keywords

Tempest Therapeutics, oncology, clinical-stage, TPST-1120, TPST-1495, PPAR antagonist, EP2/EP4 antagonist, hepatocellular carcinoma, endometrial cancer, financial results, clinical trials, FDA, ATM program, biotechnology